-+ 0.00%
-+ 0.00%
-+ 0.00%

NUVECTIS PHARMA REPORTS ENCOURAGING NXP800 INTERIM DATA SUPPORTING ONGOING ENROLLMENT IN PHASE 1B STUDY IN PATIENTS WITH PLATINUM-RESISTANT ARID1A-MUTATED OVARIAN CANCER

Reuters·11/14/2024 12:00:57

Please log in to view news